

Unit 1: Herbal Drug Industry

Free notes at pharmacolearn.fyi


Industrial Pharmacognostical Technology, subject code MPG104T, is the fourth core theory subject of M.Pharm Pharmacognosy, Semester 1. It carries 4 credits and 60 hours of theory, taught at 4 hours per week, for 100 marks. Its scope, as the syllabus states it, is to understand the industrial and commercial potential of drugs of natural origin, to integrate traditional Indian systems of medicine with modern medicine, and to know the regulatory and quality policy for the trade of herbals and drugs of natural origin. Where the earlier subjects of the semester ask what a plant contains and how it is proved, this subject asks how a plant drug becomes an industry: what infrastructure turns raw herbs into standardised extracts and finished dosage forms, what rules govern setting up and marketing that industry, how pharmacopoeias and the WHO judge its products, how natural products are tested in the laboratory and for stability, and how the law of patents protects, or refuses to protect, herbal inventions. Five units answer in order. Unit 1 covers the herbal drug industry itself. Unit 2 covers the regulatory requirements for setting it up, from global marketing and trade policy to quality assurance, TQM, GMP, GLP and ISO 9000. Unit 3 covers monographs of herbal drugs across seven pharmacopoeias and the WHO guidelines. Unit 4 covers testing of natural products, clinical laboratory testing and stability testing. Unit 5 covers patents in full, from patentability to filing, opposition, revocation and the Controllers of Patents. One discipline runs through the notes: a herbal product earns its place in trade by being standardised, documented and legally defensible, not by tradition alone.

1.1 The herbal drug industry: from field material to finished product

The herbal drug industry is the organised production of medicines and health products from drugs of natural origin: crude herbal drugs, standardised extracts, isolated phytopharmaceuticals and finished dosage forms built from them. It differs from the synthetic drug industry at its starting point. Its raw material is grown or collected, not synthesised, so its quality begins in the field, varies with season, soil, climate and handling, and must be controlled into consistency by sorting, testing, standardisation and blending. Everything in this unit, and much of Units 2 to 4, follows from that single fact: the industry is a chain that converts a variable natural material into a reproducible product, and every link in the chain exists to remove variability or to prove that it has been removed.

The chain has five broad stages. First, sourcing: cultivation under good agricultural and collection practice, or controlled collection, with botanical authentication of the species and plant part. Second, primary processing: cleaning, drying, garbling, cutting, milling and storage under conditions that protect the constituents. Third, extraction and concentration: the drug is extracted with a chosen solvent system, the extract is filtered, concentrated and dried to a powder or soft extract of defined drug extract ratio. Fourth, standardisation and testing: the extract is assayed for its marker or active constituents, checked for contaminants, and adjusted or blended so that every batch meets the same specification. Fifth, formulation and packing: the standardised extract is built into tablets, capsules, syrups, oils, ointments and other dosage forms, packed, labelled and released against finished product specifications. The production chain diagram below shows the stages.

The herbal production chain



Authentication at the start, standardisation in the middle: variability removed or proved removed

© 2026 PharmacoLearn, pharmacolearn.fyi

Figure: The herbal production chain. Authentication at the start and standardisation in the middle are the two points where a variable natural material is converted into a reproducible industrial product.

The industry works at several product levels, and an examination answer should be able to place a business on the ladder. At the base are traders and processors of crude drugs. Above them are extract manufacturers, who sell standardised extracts as industrial raw material to other companies. Above them are formulators, who buy extracts and make branded finished products. At the top are integrated companies that cultivate, extract, formulate, test and market under one control. The infrastructure, project planning and production management of the following sections apply at every level, with a scale and a regulatory burden that grow as the product moves closer to the patient.

1.2 Infrastructure of the herbal drug industry

Infrastructure means the complete working system the industry needs: land and buildings, plant and machinery, utilities, laboratories, stores, people and systems. The syllabus ties the infrastructure specifically to the production of standardised extracts and various dosage forms, so the account below follows the product.

For extracts, the core production infrastructure is a reception and raw material store with quarantine and approved areas, a cleaning and drying section, milling and sieving equipment, extraction vessels suited to the chosen process, filtration, evaporation and concentration equipment, drying equipment such as spray, vacuum or tray dryers, and blending and packing for the dried extract. For dosage forms, the infrastructure adds the formulation sections of Section 1.4: granulation, compression and coating for tablets; filling for capsules; preparation, filtration and filling lines for liquids; and melting, mixing and filling for semi solids. Around production sit the supporting areas every GMP plant needs: quality control laboratories, a quality assurance office, engineering and maintenance, purified water and steam utilities, effluent handling, warehouses for raw materials, packing materials and finished goods, and the offices that run documentation, purchase and dispatch.

Three infrastructure ideas carry examination weight. First, separation: dirty and clean operations, raw and finished goods, and different product families must be physically and procedurally separated so that cross contamination and mix ups cannot occur. Second, flow: materials should move in one direction, from receipt through quarantine, sampling, approval, processing and packing to dispatch, without backtracking through clean areas. Third, services decide quality as much as machines do: water quality, air handling, dust extraction and pest control are infrastructure, not decoration. A plant designed without them cannot be

upgraded into compliance later without rebuilding, which is why plant design is a syllabus topic of its own in Section 1.10.

1.3 Standardised extracts: the industrial product at the centre of the unit

A standardised extract is an extract adjusted, within stated limits, to a defined content of constituents with known therapeutic activity, or, where the actives are not fully known, to a defined content of marker compounds, and produced by a controlled process from an authenticated drug of defined drug extract ratio. Each element of that definition does work. Authenticated drug fixes identity. Drug extract ratio fixes the relationship between the crude drug put in and the extract taken out, so strength can be compared between batches and suppliers. Defined marker content fixes the chemical target the assay of Unit 3 and Unit 4 measures. Controlled process fixes how the target is reached, so the whole extract profile, not only the marker, stays comparable.

Industrial standardisation is achieved by the methods of the trade, stated plainly. Batches of extract are blended so that a strong and a weak batch average to specification. Inert excipients of the permitted kind may be added to adjust a strong extract down to the declared strength. Extraction conditions, solvent strength, temperature, time and drug to solvent ratio, are held inside validated ranges so the process itself delivers consistency. What standardisation is not must also be said: it is not spiking an extract with isolated or synthetic marker to fake the assay, a practice that defeats the fingerprint logic of quality control and is treated as adulteration. The case studies of Section 1.12 return to these methods in worked form.

1.4 Dosage forms built from herbal extracts

The second half of the infrastructure phrase is various dosage forms. Herbal extracts enter the same dosage form families as any other active material, each with its own herbal difficulty. Tablets and capsules carry dry extracts, with the characteristic problems of hygroscopicity, poor flow and large dose bulk, handled by granulation, suitable diluents and moisture protective packing and coating. Liquid orals, syrups, linctuses and drops carry soft or liquid extracts and traditional preparations, with problems of precipitation, microbial growth and taste, handled by filtration, permitted preservatives, sweetening and flavouring and tight container closure. Topical forms, oils, ointments, creams and gels, carry extracts and fixed and volatile oils, with problems of rancidity, separation and skin compatibility. Traditional dosage forms of the Indian systems, churnas, kwathas, asavas and aristhas, tailas and ghritas, bhasmas and others, are manufactured in their own right under the Ayurvedic, Siddha and Unani licences and pharmacopoeias of Unit 3, and the modernisation challenge of Section 1.5 is largely about bringing such forms to documented, reproducible standards without destroying their classical character. In every family the industrial questions are the same three: can the form be made identically every batch, can its quality be tested against a written specification, and does it stay within that specification for its shelf life, the stability question of Unit 4.

1.5 Current challenges in upgrading and modernisation of herbal formulations

The syllabus asks for the current challenges in upgrading and modernisation, and the honest list begins with the raw material. Variability of plant material, species confusion and substitution, declining or unsustainable wild collection, and contamination with heavy metals, pesticides and microbes all enter before manufacture begins, and no factory process fully repairs a wrong or dirty drug. The second challenge is knowledge: for many traditional formulations the active constituents are incompletely known, so standardisation must work with markers and fingerprints rather than a single active assay, and classical processes described in texts must be translated into controlled parameters of temperature, time and proportion before they can be validated. The third challenge is evidence: modernisation increasingly demands safety and efficacy data of the kind Unit 4 describes, and generating clinical evidence for multi

ingredient traditional products is slow and methodologically hard. The fourth is regulatory and commercial: different markets classify the same herbal product as a medicine, a supplement or a food, with different evidence and labelling demands, so upgrading a formulation for one market may not satisfy another, the problem behind Unit 2. The fifth is economic: modern plant, laboratories and documentation cost money that small traditional manufacturers struggle to raise, so upgrading proceeds unevenly across the industry. A good answer keeps the balance the syllabus implies: modernisation is necessary for safety, reproducibility and trade, and its challenge is to add control and evidence without discarding the traditional knowledge that made the formulations worth upgrading.

1.6 Entrepreneurship development

Entrepreneurship development is the building of the people and support system that turn technical knowledge into new herbal enterprises. In this subject it is taught as a process with recognisable stages. The prospective entrepreneur identifies an opportunity in the herbal sector, a local drug resource, an underserved product, a processing gap such as drying or extraction that cultivators cannot do themselves. The idea is then tested for feasibility: raw material availability across seasons, market demand, competition, regulatory route and cost. The enterprise is planned in the project report of Section 1.8, financed through the capital routes of Section 1.9, registered and licensed, set up, and then run through its early fragile period. Entrepreneurship development programmes, run by government agencies, industry departments, banks and training institutes, support this process with training in project preparation, finance, marketing and regulation, and with schemes of credit and subsidy directed at small industry. For pharmacy graduates the subject carries a direct message: pharmacognosy knowledge is itself an entrepreneurial asset, because the founder who can authenticate a drug, design an extraction and read a monograph can judge a herbal project from the inside, which most general investors cannot.

1.7 Project selection

Project selection is the disciplined choice of which herbal enterprise to undertake, and it is where most later success or failure is decided. The standard criteria, applied in order, form a screen that weak projects fail early. Raw material: is the drug available in the needed quantity and quality, across the year, at a workable price, from cultivation or sustainable collection, and can its identity be assured? Market: who buys the product, at what level of competition, through which channel, and is the demand durable or a passing fashion? Technology: is the process known and available, can the entrepreneur obtain the technical knowledge of Section 1.9, and does the needed machinery exist at the intended scale? Regulation: what licence and pharmacopoeial standards apply, and can the project meet GMP and testing requirements from the start? Finance: does the project size match the capital that can actually be raised, with working capital for the seasonal purchase of plant material honestly included? Location: does the site give access to raw material, labour, utilities, transport and market, without violating zoning and pollution rules? The selection flow below shows the screen as a sequence of gates.

```

Identify the herbal product or service opportunity
|
Check raw material: quantity, quality, season, sustainability
|
Check the market: buyers, competition, channel, durability
|
Check technology and technical knowledge: process available?
|
Check the regulatory route: licence, GMP, pharmacopoeia
|
Check finance: project cost against capital that can be raised
|
Check location and infrastructure
|
All gates passed: proceed to the detailed project report
Any gate failed: modify the project or select another

```

Project gates and plant zones

SELECTION GATES	PLANT ZONES	SUPPORT AREAS
Raw material secure	Receiving and quarantine	QC laboratory and QA
Market and channel	Raw material store	Water, steam, air handling
Technology available	Processing in order	Solvent and effluent care
Licence route clear	Packing and finished store	Engineering, maintenance
Finance honestly raised	Dispatch, one way flow	Offices and records

A project that fails a gate is changed or dropped before design money is spent

© 2026 PharmacoLearn, pharmacolearn.fyi

Figure: Project selection as a sequence of gates, and the plant zones those decisions produce. A project that fails a gate is modified or dropped before money is spent on design.

1.8 The project report

The project report is the written document that presents the selected project to banks, financial institutions, investors and licensing authorities, and on which the decision to finance is largely taken. Its standard contents should be known as a list. An introduction and the promoter profile, with qualifications and experience. The product description and its uses and market. The market survey: demand, supply, competition and marketing plan. The technical section: process of manufacture step by step, plant capacity in general terms, machinery list, raw material requirement, utilities and manpower. The location and site, building and layout plan. The financial section: project cost broken into land, building, machinery, preliminary expenses and working capital; the means of finance; cost of production; sales realisation; profitability estimates; break even analysis; and repayment schedule. Implementation schedule, licences and approvals needed, and supporting documents. Two qualities decide whether a report succeeds. It must be internally consistent, the capacity, raw material, cost and sales figures agreeing with each other, because lenders test exactly that. And it must be honest about assumptions, stating the prices, yields in general terms and demand basis used, since a report built on inflated assumptions produces a unit that cannot repay. In the herbal sector the technical section carries extra weight: authentication, standardisation and testing arrangements must be described, because they are what make the product lawful and saleable.

1.9 Technical knowledge and capital venture

Technical knowledge is the know how the project runs on: the process details, quality standards, machinery operation and troubleshooting skill that are not written on the product label. An entrepreneur obtains it by routes that should be listed: own professional training; employment experience in the industry; consultancy from experts and institutions; technology transfer and collaboration agreements; published pharmacopoeias, formularies and literature; and training programmes. The examination point is that technical knowledge is a project input as real as machinery: a plant bought without the knowledge to run and standardise its process produces unsaleable extract, and project appraisal therefore asks where the knowledge comes from and what it costs.

Capital venture, in the language of the syllabus, is the raising of the money the project needs, venture capital in the broad sense of risk capital committed to a new enterprise. The means of finance combine the promoter contribution, term loans from banks and financial institutions for fixed assets, working capital finance for the seasonal stock of plant material and finished goods, and, for suitable ventures, institutional venture capital and government scheme support for small and new enterprises. The herbal specifics matter. Working capital dominates, because crude drugs are bought in season and held, so cash is locked in stock for much of the year. Lenders appraise herbal projects with extra questions on raw material security and product standards, and the project report of Section 1.8 is the instrument that answers them. Capital structure must balance debt against the promoter stake so that repayment obligations do not exceed what the early, smaller sales can carry.

1.10 Plant design, layout and construction

Plant design converts the process into a building. Its principles follow directly from GMP, which Unit 2 treats as a system and which begins here as architecture. Layout starts from the flow of Section 1.2: receiving, quarantine store, sampling, approved raw material store, processing sections in process order, in process testing points, packing, finished goods store and dispatch, with personnel and material movement planned to avoid cross flow. Areas are classified by cleanliness and environmental control according to the operation performed in them, with air handling, dust control and drainage designed accordingly. Herbal specific design points deserve emphasis: generous raw material storage, because stock is bulky and seasonal; drying and milling areas with dust extraction, because plant dust is both a contamination and a safety hazard; extraction areas designed for solvent handling, with flameproof fittings and solvent recovery and storage where flammable solvents are used; and separation of strong smelling, coloured or potent drugs so they cannot contaminate others. Construction follows the design: floors, walls and surfaces that can be cleaned and do not harbour dust or microbes, adequate lighting and ventilation, water and effluent systems sized for the process, and provision for expansion, because a plant that cannot grow forces a second, disruptive rebuild. Design, layout and construction are licensed stages as well as engineering ones: factory, pollution, boiler, electrical and drug manufacturing approvals each look at the plant as built, so the design stage is where compliance is cheapest.

1.11 Pilot plant scale up techniques

Scale up is the translation of a process that works at laboratory or bench scale into one that works at production scale, and the pilot plant is the intermediate stage where that translation is proved. Direct jump from bench to factory fails for predictable reasons: mixing, heat transfer, extraction contact and drying behaviour all change with size, so a solvent ratio, time or temperature that exhausts a small batch may leave a large batch under extracted or overheated. Pilot plant scale up techniques proceed in the standard order. Define the critical process parameters at small scale: drug particle size, solvent strength and ratio, temperature, time, agitation, and the critical quality attributes of the extract, its marker content, extractive values and physical character. Run the process at pilot scale, intermediate between bench and production, holding the parameters that theory says should be held and adjusting those that scale changes, and

compare the product against the small scale specification. Identify which parameters proved scale sensitive and fix their production ranges. Then confirm at production scale with validation batches manufactured and tested exactly as routine batches will be, the results documented as the evidence that the scaled process is under control. The scale up staircase below shows the logic.




Figure: The scale up staircase. Each step proves the critical parameters at a larger size before money is committed to the next; the pilot stage is where scale sensitive parameters are found.

For herbal extracts, three scale sensitive points recur in case teaching. Extraction: percolation and maceration behaviour changes with bed depth and solvent flow, and continuous or staged extraction may replace batch soaking at scale. Concentration: long heating in large evaporators can damage heat sensitive constituents that a small rotary evaporator spared, favouring vacuum and falling film concentration. Drying: spray drying conditions that suit a pilot dryer need re establishment at production size to hold moisture and marker content together. Scale up is therefore not enlargement; it is re proof of the process at each size, and its records become part of the product history that quality assurance defends in Unit 2.

1.12 Case studies of herbal extracts

The syllabus directs case studies of herbal extracts, and their teaching value lies in a common pattern rather than in any single plant. A standardised extract case, read properly, walks through the same stations: the crude drug and its authentication; the part used and its marker or active constituents; the extraction solvent and process chosen, and why that solvent suits those constituents; concentration and drying; the specification set for the extract, identity, marker assay, limits for contaminants and physical constants; the standardisation method used to bring batches to specification, blending and adjustment of Section 1.3; the dosage forms the extract enters; and the stability behaviour that fixes its packing and shelf life. Cases commonly taught in the standard texts follow exactly this pattern for widely traded extracts such as senna standardised on its sennosides, liquorice on glycyrrhizin, and other marker led extracts of the pharmacopoeias. Read any case by asking the station questions in order: what proves identity, what is measured to prove strength, what process decisions protect the constituents, and what specification would catch a bad batch?

1.13 Formulation and production management of herbals

Production management is the running of the approved process, day after day, so that output, quality and cost stay together. Its instruments are standard in industry and take herbal colouring from the material. Production planning starts from the sales plan and the seasonal raw material position: extraction campaigns are scheduled when authenticated drug is available and approved, and batch sizes are set to the plant and the stock position. Batch manufacturing records document each batch from dispensing to release, with the in process checks, yields in process terms and deviations recorded as they happen, so any batch can be traced back to its drug lot and forward to its customers. Inventory management balances the cost of holding seasonal stock against the risk of stock out, with stores run on first expiry first out for materials and products with shelf lives. Personnel management provides trained operators for each operation, with training records, because most deviations trace back to an untrained hand or an unclear instruction. Maintenance and calibration keep machinery and instruments in their validated state. Cost management watches the few costs that dominate herbal manufacture: raw material, solvent and its recovery, energy for drying, and testing. Production management closes Unit 1 where it began: the industry exists to convert variable nature into reproducible product, and management is the discipline that performs that conversion on schedule, at cost and inside the rules that Unit 2 now sets out.

*More free M.Pharm notes and unit wise PDFs at pharmacolearn.fyi
Free video lectures on the PharmacoLearn YouTube channel*